Soterix Medical has snapped up the CE Mark for its 1x1 tDCS therapy system for the treatment of major depressive disorder.

The noninvasive, nonsystemic therapeutic device delivers low-intensity direct current to a region of the cerebral cortex in the brain, which is responsible for controlling mood.

According to the New York, N.Y.-based company, the system does not have the side effects commonly associated with oral antidepressant medications. — Michael Cipriano